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The complex disorder Cantu syndrome (CS) arises from gain-
of-function mutations in either KCNJ8 or ABCC9, the genes
encoding the Kir6.1 and SUR2 subunits of ATP-sensitive potas-
sium (KATP) channels, respectively. Recent reports indicate that
suchmutations can increase channel activity bymultiplemolec-
ular mechanisms. In this study, we determined the mechanism
by which KATP function is altered by several substitutions in
distinct structural domains of SUR2: D207E in the intracellular
L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in
TMD2. We engineered substitutions at their equivalent posi-
tions in rat SUR2A (D207E, Y981S, G985E, M1056I, and
R1150Q/R1150W) and investigated functional consequences
using macroscopic rubidium (86Rb) efflux assays and patch-
clamp electrophysiology. Our results indicate that D207E
increases KATP channel activity by increasing intrinsic stability
of the open state, whereas the cluster of Y981S/G985E/M1056I
substitutions, as well as R1150Q/R1150W, augmented Mg-nu-
cleotide activation. We also tested the responses of these chan-
nel variants to inhibition by the sulfonylurea drug glibencl-
amide, a potential pharmacotherapy for CS. None of the D207E,
Y981S, G985E, or M1056I substitutions had a significant effect
on glibenclamide sensitivity.However,Gln andTrp substitution
at Arg-1150 significantly decreased glibenclamide potency. In
summary, these results provide additional confirmation that
mutations in CS–associated SUR2 mutations result in KATP
gain-of-function. They help link CS genotypes to phenotypes
and shed light on the underlying molecular mechanisms,
including consequences for inhibitory drug sensitivity, insights
that may inform the development of therapeutic approaches
to manage CS.
ATP-sensitive potassium (KATP) channels are potassium-se-
lective ion channels formed by obligate co-assembly of pore-
forming Kir6.x subunits and regulatory sulfonylurea receptors
(SURx)3 in a 4:4 stoichiometry (1–4). Channel opening is
dynamically regulated by intracellular nucleotides and mem-
brane phospholipids and thereby couples themembrane poten-
tial of excitable cells to their metabolic state (5). By binding
to, and stabilizing, closed states of the Kir6.x subunit, ATP
decreases channel open probability, whereas magnesium-nu-
cleotide complexes (MgADP and MgATP) bind to the nucle-
otide-binding domains (NBDs) of SURx subunits to activate the
channel (6, 7).
In cardiac, smooth, and skeletal muscle, SUR2 subunits (of
which there are two main splice variants, SUR2A and SUR2B)
co-assemble variously with Kir6.1 (as in vascular smooth mus-
cle) or Kir6.2 (as in ventricular and skeletalmuscle) (8, 9). In the
heart, Kir6.2/SUR2A KATP channels have been proposed to be
critical for ischemic pre-conditioning, whereas in skeletal mus-
cle Kir6.2/SUR2A channels may provide a “brake” to hyperpo-
larize the membrane potential despite elevations in intra-
cellular calcium during periods of exercise and increased
metabolism (9, 10). In smooth muscle, Kir6.1/SUR2B KATP
activity is a key determinant of electrical excitability and con-
sequent contractility in blood and lymphatic vessels, as well as
in bladder and uterine muscle (11–15).
There have now been multiple reports of mutations in the
ABCC9 and KCNJ8 genes (which encode SUR2 and Kir6.1,
respectively) associated with the complex heritable disorder,
Cantu syndrome (CS) (16–21). CS patients exhibit diverse car-
diovascular features, including dilated and tortuous vessels,
cardiomegaly, electrophysiological alterations in the cardiac
conduction system, decreasedneurovascular coupling, andper-
sistence of fetal circulation (16–18, 20–25). An emerging
model for the molecular basis of CS is that missense mutations
in ABCC9 or KCNJ8 result in increased KATP channel activity
and consequently reduced smoothmuscle excitability and con-
tractility (26, 27). CS–associated mutations in SUR2 have pre-
viously been shown to result in KATP channel gain-of-function
(GoF) by distinct mechanisms, including enhanced Mg2-nu-
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cleotide activation and increased intrinsic open probability
with consequent decreases in ATP inhibition (18, 19). Here, we
examined the functional effects of previously uncharacterized
CS mutations that are predicted to cluster together at the link
between NBD1 and TMD2: Y981S (human Y985S), G985E
(G989E), and M1056I (M1060I) (Fig. 1), and we compared the
molecular consequences to those ofD207E, located in the intra-
cellular L0-linker, between TMD0 and TMD1 (Fig. 1). In addi-
tion, the sensitivity of mutant channels to the sulfonylurea
KATP-inhibitor glibenclamide was tested. Glibenclamide holds
promise as a potential treatment for CS, although numerous
Kir6.2- and SUR1-dependent KATP GoF mutations, which
reduce sulfonylurea sensitivity, have previously been reported
(28–30). Therefore, determining sulfonylurea sensitivity for
specific mutations may be required for future individualized
therapy. The results are interpreted alongside structural
insights from recently reported high resolution cryo-EM struc-
tures of KATP channel complexes (3, 4) to provide further detail
of the molecular basis of KATP channel GoF in CS.
Results
Case history of subject with SUR2(Y985S)mutation
The subject is the fourth child of healthy, unrelated Cauca-
sian parents, with no family history of relevance to her condi-
tion. The pregnancy was complicated with raised nuchal trans-
lucency at 12 weeks and polyhydramnios at 32 weeks of
gestation. At 38 weeks of gestation, labor was induced, with
uncomplicated vaginal delivery. Birth weight was 5.3 kg (99
centile). There was no significant delay in early development,
but language skills developed slowly. At birth, hypertrichosis
was evident,with a full headof darkhairwith lowanteriorhairline;
shoulders, arms, legs, and back were covered with long, thick, and
dark hair. At 3 years of age, facial features were rather coarse, with
mild epicanthic folds anddown-slanting palpable fissureswith full
lips and a broad face. The forehead was extremely low with fine
hair in front of the ears, extending over her chin, and hypertricho-
sis over her neck and chest. The heart was slightly enlarged, but
there was no overt evidence of cardiomyopathy.
At age 5, the subject presented with recurrent respiratory
infections and required hospital admission for pneumonia,
leading to tonsillectomy and adenoidectomy, which improved
severe snoring and obstructive sleep apnea. Height was on the
50th centile, weight on the 91st centile, and her head circumfer-
ence was on the 98th centile. Facial features remained coarse with
down-slanting palpable fissures, full cheeks, broad tip to the nose
withmild thickening of the alae nasae, and a lowcolumella. Signif-
icant joint laxity was evident in the hands, with deep palmar
creases and soft skin on the palms and generous fetal finger pads.
This subject thus exhibited most of the features typically
found in individuals with CS (18, 24). Sequencing of ABCC9-
coding regions revealed a heterozygous mutation (c.2954A3
C, p.Y985S) that was absent in genomic DNA from either par-
ent. Heterozygous de novo mutations (p.G989E; p.M1060I)
were also identified in two additional diagnosedCS subjects, for
whom clinical details are not available. The three mutated res-
idues are predicted to cluster in a similar location within the
SUR2 protein (Fig. 1). We therefore analyzed the molecular
consequences of these mutations and compared them with the
Figure 1. Structure of KATP channels. A, KATP channels form as hetero-octamers of four pore-forming Kir6.x subunits each associatedwith a SUR subunit (two
SUR subunits omitted from figure). B, schematic representation of the position of D207E, Y981S, G985E, M1056I, and R1150Q/R1150W in the linear sequence
of SUR2. C, expected positions of D207E, Y981S, G985E, M1056I, and R1150Q/R1150Wmapped onto the pancreatic KATP (Kir6.2/SUR1; Protein Data Bank code
5WUA) structure (4). The residues shownare theanalogouspositions inhamster SUR1 (Asp-209, Tyr-1004,Ala-1008, Thr-1089, andArg-1183, respectively; there
is 70% sequence identity between hSUR1 and rSUR2A, and structural the domains are expected to be conserved). ATP is modeled in the Kir6.2-binding site.
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consequences of the most common CS mutation (p.R1154Q),
and another uncharacterized CS mutation p.D207E (16),
located in distinct SUR2 domains.
Cantu syndromemutations result in gain-of-function of KATP
channel in intact cells
To determine the effect of mutations on KATP channel func-
tion, SUR2A constructs were co-expressed with Kir6.2 in
Cosm6 cells, and channel activity was assessed using a radioac-
tive 86Rb flux assay. First, basal KATP activity under quasi-
physiological regulation by intracellular nucleotides in intact
cells was determined by measuring 86Rb efflux from cells
bathed in Ringer’s solution. As shown in Fig. 2, A and B, the
KATP-dependent 86Rb efflux rate in these conditions was sig-
nificantly increased by the D207E, G985E, and M1056I substi-
tutions, although a trend toward an increase was observed for
Y981S. Efflux rates in basal conditions are a function of both
channel activity and surface membrane expression. We
assessed efflux rates in cells subjected to metabolic inhibition
(MI) to decrease intracellular ATP synthesis and relieve chan-
nels of nucleotide regulation. Assuming that the single channel
conductance is unaffected and that MI maximally activates
available channels, the comparison of the MI efflux rate
between constructs provides an estimation of the relative num-
ber of channels in the membrane. As shown in Fig. 2, C and D,
there was a statistically insignificant decrease in Y981S efflux
rate, and a statistically insignificant increase in MI efflux rate
was observed for D207E, implying that these mutations result
in only a small decrease or increase, respectively, in channel
number. Otherwise, the maximum flux under these conditions
was notmarkedly different between constructs, suggesting that
the number of active channels was similar.
All known CS patients are heterozygous, and we modeled
heterozygous conditions by co-expressing Kir6.2 together
with WT SUR2A and mutant SUR2A subunits at a 1:1 ratio.
The resultant channels were assayed by monitoring 86Rb
efflux. Only very minor increases in basal efflux rate were
observed for D207E, G985E, and M1056I, although a
moderate, statistically significant increase was observed for
Y981S channels (Fig. 3). Taken together, these data demon-
strate that whereas all tested mutations result in KATP gain-
of-function, in heterozygous conditions the effect is subtle
under basal conditions.
D207E in the L0-linker increases open-state stability and
decreases ATP inhibition
Increased basal KATP channel activity could arise from
changes in multiple distinct nucleotide-sensing mechanisms,
Figure 2. D207E, G985E, and M1056I significantly increase basal KATP channel activity in intact cells. A, cumulative
86Rb efflux was measured from
Cosm6 cells transfected either with GFP alone or with Kir6.2 plus WT or mutant SUR2A. Efflux as a function of time was first recorded in basal conditions (cells
incubated in Ringer’s solution) (A), and the KATP-dependent efflux rate was attained from exponential fits to efflux time data (B). Second, efflux was measured
from cells subjected toMI (induced by incubation in Ringer’s solutionwith 2.5mg/ml oligomycin and 1mM2-deoxy-D-glucose from10min prior to commenc-
ing the flux assay) (C), and the rate constant for KATP-dependent efflux in MI was calculated from exponential fits to the early time points (2.5, 5, and 12.5 min)
(inset, C and D). Efflux-time data are shown as mean  S.E., and KATP-dependent efflux rate scatter plots show mean  S.D. from 3 to 5 independent
experiments. Statistical significance is denoted by asterisk and defined as p 0.05 according to Mann-Whitney U test.
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including increased Mg-nucleotide activation or decreased
ATP inhibition, either as a result of decreased binding affinity
or decreased efficacy due to increase in intrinsic open-state
stability (19). To investigate the effects of the above mutations
on nucleotide sensitivity, we used inside-out patch-clamp
recordings. As shown in Fig. 4, channels comprising Kir6.2
and WT SUR2A were inhibited by ATP in the absence of
Mg2 with an IC50 of 15 M. In the presence of Mg2, the
IC50 was20 M. The presence of Mg2 results in increased
channel activity for a given ATP concentration, resulting
from mixed effects of the MgATP activation and magnesium-
independent ATP inhibition, and is reflected in a right-shift
in the MgATP dose-response curve, relative to Mg2-free
ATP. The sensitivity of D207E-containing channels to both
MgATP and Mg2-free ATP was reduced 3-fold in each
case, with IC50 in Mg2-free ATP of 40 and 55 M,
respectively (Fig. 4).
The relationship between the IC50 in ATP in the presence
and absence of Mg2 (IC50[MgATP]/IC50[ATP]) can provide
an indirect measure of the extent of Mg2-nucleotide activa-
tion. For D207E andWTSUR2A, the IC50[MgATP]/IC50[ATP]
was very similar (1.5), indicating that sensitivity toMg2 acti-
Figure 3. Y981S confers gain-of-function when co-expressed with WT subunits in intact cells whereas only minor effects are observed for other
mutations.Cumulative 86Rb effluxwasmeasured fromCosm6 cells transfected eitherwithGFP alone orwith Kir6.2 alongside SUR2A-WT alone or SUR2A-WT
with mutant SUR2A at a 1:1 ratio. Basal efflux shown as function of time (A), and KATP-dependent efflux rate constants were calculated (B). Efflux rate was
measured in MI conditions (induced by incubation in Ringer’s solution with 2.5 mg/ml oligomycin and 1 mM 2-deoxy-D-glucose from 10 min prior to com-
mencing the flux assay) (C), and rate constants were calculated from early time points (2.5, 5, and 12.5 min) (inset, C and D). Efflux-time data are shown as
mean S.E., andKATP-dependent efflux rate scatter plots showmean S.D. from3 to5 independent experiments. Statistical significance is denotedbyasterisk
and defined as p 0.05 according to Mann-Whitney U test.
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vation was unaffected by this mutation (Fig. 4F) and suggesting
that GoF results from decreased sensitivity to inhibitory ATP
itself. Considering the location of this residue, predicted to be in
close proximity to the ATP-binding site on Kir6.1 in the octa-
meric KATP complex (3, 4), this could conceivably arise from
altered binding affinity. Alternatively, decreased ATP sensitiv-
ity could be the result of enhanced open-state stability of chan-
nels (19, 31). To test the latter directly, we measured the
response of channels to PIP2 perfused onto the intracellular
surface of excised membrane patches (Fig. 5). PIP2 increases
openprobability (Po) to1, and the ratio of initial current levels
to the activated level in PIP2 provides an estimate of the initial
“intrinsic” Po (28). As shown in Fig. 5, the intrinsic Po was
increased from0.4 inWT to0.7 in D207E channels. There-
fore, the D207E mutation within the L0-linker results in KATP
gain-of-function by increasing the intrinsic open probability of
channels, rather than by decreasing inhibitory ATP binding
affinity.
Mutations within the Y981/G985/M1056 cluster increase
Mg2-nucleotide activation
The disease-associated mutations Y981S, G985E, and
M1056I are all clustered together on transmembrane helices 12
and 13 in TMD2 (Fig. 1). In comparison with WT SUR2A, the
IC50 for ATP inhibition in the presence of Mg2 was signifi-
cantly increased by each of these mutations; however, in con-
trast to D207E, there was no effect on ATP sensitivity in the
absence of Mg2 (Fig. 6). This is further demonstrated by the
increase in IC50[MgATP]/IC50[ATP] for all mutants (Fig. 6G),
indicating that the mutations in this cluster of residues linking
Figure 4. D207E provokes decreases in ATP inhibition in the presence and absence ofMg2. Inside-out patch-clamp recordingsweremade fromCosm6
cells transfected with Kir6.2 plus either SUR2A-WT or D207E. The response to MgATP was determined from voltage-clamped patches (50 mV), as shown in
representative traces (scale bars denote 500 pA/5 s unless otherwise stated) (A). ATP inhibition in the absence of Mg2 was also determined from voltage-
clamped patches (50 mV), as shown in representative traces (B). Kir6.2/SUR2A-WT channels were inhibited by ATP in the presence of Mg2 with an IC50 of
21.3 3.0 M (Hill coefficient 1.3 0.1; n 16) and by ATP in the absence of Mg2with an IC50 of 14.4 2.3 M (Hill coefficient 1.2 0.1; n 14). This was
increased in both cases by the D207E mutation; here, the IC50 for ATP in the presence of Mg
2was 55.8 11.9 M (Hill coefficient 1.2 0.1; n 9), and
by ATP in the absence of Mg2 with an IC50 of 39.9 6.0 M (Hill coefficient 1.2 0.1; n 9) (C). Scatter plots show data from individual experiments
with mean IC50  S.D. D and E, notably, the ratio of the IC50 for ATP in the absence and presence of Mg
2 was unchanged by the D207E mutation,
indicating the mutation had little effect on Mg2-nucleotide activation (F). Statistical significance is denoted by asterisk and defined as p  0.05
according to Mann-Whitney U test.
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Figure 6. Y981S, G985E, and M1056I cause KATP GoF by enhancing Mg
2-nucleotide activation. Inside-out patch-clamp recordings were made from
Cosm6 cells transfected with Kir6.2 alongside mutant SUR2A. The response to ATP in the presence (left) and absence (right) of Mg2 was determined from
voltage-clampedpatches (50mV) of cells expressing either Y981S (A), G985E (B), orM1056I (C), as shown in representative traces (scale barsdenote 500 pA/5
s unless otherwise stated). Analysis of dose-response experiments showed that each mutation increased the IC50 for MgATP compared with WT (MgATP IC50
for Y981S was 39.6 7.3M, Hill coefficient 1.2 0.1, n 6; MgATP IC50 for G985E was 48.4 8.7M, Hill coefficient 1.1 0.1, n 11; MgATP IC50 for M1056I
was 91.9  14.4 M, Hill coefficient 1.7  0.2, n  6), with little effect on ATP inhibition in the absence of Mg2 (ATP IC50 for Y981S was 11.8  2.2 M, Hill
coefficient 1.0 0.1, n 4; ATP IC50 for G985E was 17.5 4.7M, Hill coefficient 1.1 0.1, n 6; ATP IC50 for M1056I was 10.0 5.6M, Hill coefficient 0.9
0.1, n 3) (D). Scatter plots show data from individual experiments with mean IC50 S.D. (E and F). Decreased ATP inhibition in the presence of Mg
2 only is
demonstrated by the ratio of the IC50 for ATP in the presence and absence of Mg
2, which is markedly increased for Y981S, G985E, and M1056I (G). Statistical
significance is denoted by asterisk and defined as p 0.05 according to Mann Whitney U test.
Figure 5. D207E increases intrinsic open-state stability. Inside-out patch-clamp recordings weremade from Cosm6 cells transfected with Kir6.2 alongside
either SUR2A-WT or D207E. Patches were administered 3 mM ATP followed by washout and administration of 5 g/ml PIP2 to maximally increase channel
activity, as indicated on representative traces (A). The stable peak current observed in PIP2 was divided by the current observed in the absence of nucleotides/
PIP2 to determine the level of basal channel activity. D207E channels displayed increased basal activity (I[basal]/I[PIP2] was 0.44  0.08 for SUR2A-WT and
0.73 0.06 for D207E; scatter plot shows data from individual experiments with mean S.D. from seven patches) (B). Statistical significance is denoted by
asterisk and defined as p 0.05 according to Mann Whitney U test.
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NBD1 to TMD2 increase channel activity by enhancing Mg2-
nucleotide activation.
R1150Q and R1150W in TMD2 also enhanceMg2-nucleotide
activation
Having established that the TMD2 Y981S, G985E, and
M1056I mutations enhance Mg2-nucleotide activation, we
sought to test whether this mechanismwas conserved for other
TMD2mutations, and themost commonCS–associatedmuta-
tions are R1150Q and R1150W. In agreement with a previous
report (16), we show that R1150Q causes a large increase in
MgATP IC50, whereas R1150W has a more modest effect (Fig.
7). In contrast, R1150Q and R1150W caused only slight
increases in ATP IC50 (Fig. 7), again reflected in increased
IC50[MgATP]/IC50[ATP] for R1150Q and R1150W (Fig. 7F),
and thus both R1150Q and R1150W cause gain-of-function
predominantly by enhancing Mg2-nucleotide sensitivity.
Effect of CS GoFmutations on glibenclamide sensitivity
Glibenclamide (glyburide) inhibits KATP channels in a
biphasic manner, with high-affinity inhibition arising from
interaction with the SUR subunit occurring at nanomolar to
micromolar concentrations and low-affinity inhibition due
to interaction with the Kir6.x subunit (32). To specifically
measure high-affinity inhibition, we applied glibenclamide
up to 10 M. Glibenclamide inhibited WT SUR2A KATP cur-
rents (in the absence of nucleotides), as well as D207E,
Y981S, G985E, and M1056I (Fig. 8), with maximal inhibition
of 70% and IC50 values ranging from 15 to 45 nM. In
contrast, mutations at residue 1150, in particular R1150W,
Figure7.R1150QandR1150WalsocauseKATPGoFbyenhancingMg
2-nucleotideactivation.The response toMgATP (A) andATP in theabsenceofMg2
(B) was determined for channels expressing Kir6.2with R1150Qor R1150W, by inside-out patch-clamp recordings fromCosm6 cells as shown in representative
traces (scale barsdenote500pA/5 sunlessotherwise stated).Dose-responseanalysis (C) demonstrated thatbothmutationsmarkedly increased the IC50 forATP
in the presence of Mg2, comparedwithWT (MgATP IC50 for R1150Qwas 163.7 36.8M, Hill coefficient 2.3 0.3, n 6; MgATP IC50 for R1150Wwas 46.0
7.8 M, Hill coefficient 1.2 0.2, n 6). The effect on ATP sensitivity in the absence of Mg2was more modest for both mutations (ATP IC50 for R1150Q was
17.3 4.3M, Hill coefficient 1.2 0.2, n 8; ATP IC50 for R1150Wwas 20.6 3.4M, Hill coefficient 1.3 0.2, n 10). Scatter plots showdata from individual
experiments withmean IC50 S.D. (D and E). An increase in the ratio of the IC50 for ATP in the presence over the IC50 for ATP in the absence of Mg
2 indicates
that these mutations also predominantly confer GoF by augmentation of Mg2-nucleotide activation (F). Statistical significance is denoted by asterisk and
defined as p 0.05 according to Mann-Whitney U test.
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resulted in a significant decrease in glibenclamide potency
(Fig. 9).
Discussion
Cantu syndrome–associated ABCC9mutations all cause KATP
GoF
Todate, the few analyzedCantu syndrome–associatedmuta-
tions in ABCC9 (SUR2), have been shown to result in gain-of-
function of KATP channels in the presence of Mg2-nucleo-
tides, which can arise either from decreased sensitivity to
inhibitory ATP, or augmented activation by Mg2-nucleotides
(16, 19). In this study, we have demonstrated that four previ-
ously uncharacterized mutations in SUR2 (D207E (human
D207E), Y981S (Y985S), G985E (G989E), and M1056I
(M1060I)) lead to increased channel activity in the presence of
regulatory nucleotides via diversemolecularmechanisms. As in
previous reports, we used Kir6.2/SUR2A channels for analysis
due to the difficulty of recording Kir6.1/SUR2 currents,
although it is expected that the mechanism of SUR2 mutations
will be conserved irrespective of the pore-forming subunit. In
addition, although the dependence of channel activity on intra-
cellular nucleotides differs quantitatively between the two
major SUR2 splice variants (SUR2A and SUR2B, which differ
only in their C-terminal exon) (33, 34), it is anticipated that,
qualitatively, the changes observed for mutant SUR2A-con-
taining channels will be common for SUR2B-containing chan-
nels. Interestingly, many CS features such as vascular dilatation
and lymphedema likely arise from smooth muscle dysfunction,
whereas the effects on cardiac electrophysiology and skeletal
muscle are less obvious (24). Thismay suggest that the biophys-
ical effects of mutations are more severe in SUR2B-containing
channels than in SUR2A-containing channels. Alternatively, it
is possible that the predominantly smooth muscle conse-
quences of CS arise due to the physiological context of KATP
function in smooth muscle rather than unique biophysical
effects on SUR2B compared with SUR2A.
Mechanistic basis of GoF varies betweenmutations
Here, we compared the sensitivity of wildtype and mutant
channels to ATP in the absence and presence of Mg2 to sepa-
rate the Mg2-independent inhibitory effect of ATP from the
activating effect ofMgATP. This analysis shows that theD207E
mutation reduces ATP inhibition itself, whereas the Y981S/
G985E/M1056I mutations all increase activity by enhancing
MgATP activation. The D207E mutation is found in the intra-
cellular L0-linker between the two transmembrane domains
TMD0 and TMD1 (Fig. 1). A critical role of the L0-linker in
determining channel-gating properties has been suggested for
both SUR1 and SUR2 (35, 36). Recent high-resolution struc-
tures of the related Kir6.2/SUR1 KATP channel complex con-
firm earlier predictions that the L0-linker is closely apposed to
the intracellular domains of the Kir6 subunit, and likely it pro-
vides a structural interaction between the subunits that is
involved in the transduction of functional signals. Interestingly,
multiple mutations in the L0-linker of SUR1 have been
reported in neonatal diabetes patients, including the analogous
mutation to D207E (37). Functional characterization of
L0-linker mutations in SUR1 show that channel activity is
increased due to elevations in the intrinsic channel open prob-
ability, arising from decreased occupation of long-lived, ATP-
accessible closed states (35). Consistent with this finding, we
show that enhanced basal open probability of D207E-contain-
ing channels, reflected in decreased PIP2 activation, underlies
decreased sensitivity to inhibitory ATP (Figs. 4 and 5).
Figure 8. D207E, Y981S, G985E, andM1506I haveno significant effect onglibenclamide sensitivity. Inside-out patch-clamp recordingsweremade from
Cosm6 cells transfected with Kir6.2 alongside WT or mutant SUR2A. Reversible inhibition was observed following administration of increasing glibenclamide
concentrations, as shown in representative traces (scale bars denote 500 pA/5 s unless otherwise stated) (A). Dose-response analysis demonstrated that only
minor, non-statistically significant variations in glibenclamide IC50 values were observed for these mutations (IC50 for SUR2A-WT was 29.5  11.1 nM, Hill
coefficient 1.0 0.1, n 11; IC50 for D207Ewas 42.8 11.4 nM, Hill coefficient 0.7 0.1, n 4; IC50 for Y981S 13.1 5.9 nM, Hill coefficient 0.9 0.1, n 3; IC50
for G985E 39.2  9.8 nM, Hill coefficient 1.0  0.2, n  4; IC50 for M1056I 47.3  13.8 nM, Hill coefficient 1.0  0.4, n  4) (B). Scatter plots show data from
individual experiments with mean IC50 S.D. (C). Statistical significance was determined using Mann-Whitney U tests.
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In contrast, we show that the Y981S, G985E, and M1056I
mutations all act by increasing KATP channel activation by
MgATP (Fig. 6). These residues are all predicted to lie in close
proximity to each other in a cluster within TMD2; Tyr-981 and
Gly-985 are found at theN-terminal end of TM12, immediately
following the NBD1-TMD2 linker, whereas M1056I is situated
on the opposing TM13 (Fig. 1). The location of the Tyr-981/
Gly-985/Met-1056 cluster, at the link between the NBDs and
the TM domains (Fig. 1), is appropriate for transduction of
movements between the intracellular and transmembrane
domains of SUR2. Biochemical analyses of SUR and related
ABC proteins indicate that MgADP or MgATP binding to the
NBDs of SUR may act to stabilize dimerization of NBD1 and
NBD2 (7, 38, 39). However, how binding or NBD dimerization
is coupled to gating of the channel pore remains poorly
understood.
The concentration of free Mg2 varies in different cell types
(40); in cardiomyocytes (which express Kir6.2/SUR2A), free
Mg2 is reported to be0.5mM, the concentration used in this
study (41). As free Mg2 levels are tightly regulated in most
cells, the physiological effect of CS mutations that alter Mg2
nucleotide sensitivity will be altered responses to nucleotide
concentrations (in the presence of Mg2), not to changing
Mg2 concentrations (9).
In addition, we show that the previously reported common
CS mutations R1150Q and R1150W (located in TM15 of
TMD2) also enhanceMgATPactivation (Fig. 7), demonstrating
that multiple transmembrane regions of TMD2 are involved in
the conformational changes associated with Mg2-nucleotide
activation.
Notably, the gain-of-function induced by each mutation is
quite subtle when mutant and WT SUR2A subunits are co-ex-
pressed to mimic the clinically relevant heterozygosity (Fig. 2).
Recent reports of GoF mutations in Kir6.2 and SUR1 that
underlie neonatal diabetes demonstrate that even very subtle
biophysical effects can result in disease (42), suggesting that
dramatic changes may not be necessary. In contrast, because
SUR2B may be the more pathologically relevant splice variant,
it is possible that these mutations will have a greater effect on
channels containing SUR2B. In addition, the channel activity
measured in 86Rb experiments under basal conditions may
not fully recapitulate the metabolic and physiological context
for KATP channels in muscle or other differentiated cell types,
and so we cannot rule out a more significant activating effect
under other conditions.
Consequences for sulfonylurea sensitivity
Previous studies have demonstrated that second generation
sulfonylureas such as glibenclamide inhibit SUR2-containing
KATP channels, albeit with lower potency than SUR1-contain-
ing channels (43). As such, glibenclamide, or other sulfony-
lureas, represents a potential pharmacotherapy for CS. How-
ever, there are multiple reports of neonatal diabetes mutations
in theKir6.2/SUR1KATP subunits that reduce sulfonylurea sen-
sitivity (28, 29) and, as we have recently demonstrated, the
CS–associated mutation V65M in Kir6.1 profoundly reduces
glibenclamide inhibition of recombinant channels (30). There-
fore, it is important to assess the effect of SUR2 CS mutations
on inhibitor sensitivity. Here, we show that the D207E, Y981S,
G985E, and M1056I mutations do not obviously affect gliben-
clamide sensitivity (Fig. 8). It has been reported that sulfony-
lurea inhibition of SUR2-containing channels is affected by
nucleotide regulation (44, 45), and so it is possible that these
mutations may alter SU sensitivity under more complex phys-
iological regulation, but this remains to be established.
A decrease in glibenclamide potency was observed in both
the R1150Q andR1150Wmutations (Fig. 9). Interestingly, Arg-
1150 lies in TM15 (Fig. 1), and previous studies have demon-
strated that TMs 14–16 are critical for high-affinity SU binding
to SUR subunits (46, 47). Indeed, serine to tyrosine substitution
of a single residue in TM16 (predicted to lie within 15 Å of
Arg-1150 on the cytoplasmic extensions of the TM helix) is
sufficient to confer SUR2-like sensitivity to SUR1, and vice
versa (46, 47). This raises the possibility that the Arg-1150
mutations may directly decrease glibenclamide sensitivity via
disruption of the drug-binding site. The R1150W mutation
exhibited a more pronounced effect than the glutamine muta-
tion at the same site, perhaps due to a greater steric effect of the
Figure 9. R1150Q and R1150Wdecrease glibenclamide sensitivity.Glibenclamide sensitivity wasmeasured from inside-out patch-clamp recordings from
Cosm6 cells expressing Kir6.2 with either SUR2A-WT, R1150Q, or R1150W as shown in representative traces (scale bars denote 500 pA/5 s unless otherwise
stated) (A). Dose-response analysis shows that bothR1150QandR1150W induce a statistically significant decrease inglibenclamide sensitivity (IC50 for R1150Q
was 86.3 23.4 nM, Hill coefficient 0.8 0.3, n 5; IC50 for R1150W was 303.5 91.1 nM, Hill coefficient 0.8 0.1, n 5) (B). Scatter plots show data from
individual experiments with mean IC50 S.D. (C). Statistical significance was determined using Mann-Whitney U tests; *, p 0.05.
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bulky tryptophan side chain. Regarding the relevance to treat-
ability of disease, it is important to note that glibenclamide
sensitivity was evaluated in a “homozygous” context where all
SUR2 subunits were mutated, but all CS patients identified so
far are heterozygous. The data highlight the relatively minor
effect of most mutations on drug sensitivity, although they sug-
gest that the Arg-1150 mutation may reduce SU sensitivity in
patients. Potentially, studies of native channels in human-in-
duced pluripotent stem cell-derived cardiovascular cells may
allow more accurate assessment of the potential impact of CS
mutations on the pharmacological response.
Taken together, these results provide further evidence for
KATP gain-of-function consequences of SUR2 mutations in
Cantu syndrome. For several mutations clustered in TM12–13,
the results illustrate a commonmechanism (enhancedMgATP
activation) without marked effect on sulfonylurea sensitivity.
The results provide novel insights into the function of KATP
channel complexes, can be useful for linking CS genotype to
phenotype in this complex disorder, and will inform the con-
sideration of therapeutic approaches to CS.
Experimental procedures
Molecular biology and cell culture
Mutations were introduced into a rat SUR2A (pCMV_
rSUR2A; GenBankTM accession no. D83598.1) cDNA con-
struct using site-directed mutagenesis and verified by direct
Sanger sequencing. The residue numbering refers to the
rSUR2A clone, which shares 97% sequence identity with the
human sequence and was used to allow for comparison with
previous reports of the effects of other Cantu syndrome muta-
tions that also used rSUR2A. Cosm6 cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) and transfected
using FuGENE 6 (Roche Applied Science) with wildtype
pcDNA3.1_mKir6.2 (0.6 g; GenBankTM accession no.
D50581.1) and wildtype or mutant pCMV_rSUR2A constructs
(1g) in addition to 0.2g of pcDNA3.1_eGFP for visual detec-
tion of successful transfection. To model heterozygous expres-
sion of mutant subunits, cells were transfected withWT Kir6.2
along with a 1:1 ratio of WT and mutant rSUR2A (0.5:0.5 g).
Radioactive rubidium efflux experiments were performed 36 h
post-transfection, while the excised patch-clamp recordings
were made 48–72 h post-transfection.
86Rb efflux assay
Transfected Cosm6 cells were plated in 12-well plates to
reach 70–80% confluence on the day of experimenting. Prior to
commencing the efflux assay, the culturemediumwas replaced
by DMEM supplemented with 1 Ci/ml 86RbCl (PerkinElmer
Life Sciences) and incubated for 6 h (37 °C/5% CO2) to load
the cells with the 86Rb isotope. After the loading incubation,
cells were washed with Ringer’s solution containing (in mM)
118 NaCl, 10 HEPES, 25 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 2.5
CaCl2, and 1.2 MgSO4 either alone or supplemented with 2.5
mg/ml oligomycin and 1mM 2-deoxy-D-glucose to inducemet-
abolic inhibition (MI) and incubated at room temperature for a
further 10 min. Cells were then washed three times with Rin-
ger’s solution (either with or without MI supplements) before
the experiment was commenced. Ringer’s solution was added
to each well, collected, and replaced at the defined time points
(2.5, 5, 12.5, 22.5, and 37.5 min). After the experiment, cells
were lysed with 2% SDS to attain the remaining intracellular
86Rb, and sample radioactivitywas determined by scintillation
counting.
The cumulative 86Rb efflux at each time point was calcu-
lated from the total counts from each sample (including the
86Rb remaining post-cell lysis). Apparent KATP-independent
efflux rate constants (k1) were obtained from GFP-transfected
cells using Equation 1,
efflux 1 ek1  t (Eq. 1)
and KATP-dependent efflux rate constant (k2) was obtained
from KATP-transfected cells using Equation 2,
efflux 1 e		k1  t
 	k2  t

 (Eq. 2)
where k1 was obtained fromGFP-transfected cells (Equation 1).
The number of active channels was assumed to be proportional
to k2. In MI conditions a time-dependent divergence from a
mono-exponential efflux is observed. This is attributed to inac-
tivation of background effluxmechanisms over time; therefore,
in this condition rate constants were derived from exponential
functions fit to early time points only (2.5–12.5 min). Efflux-
time data shown represents the mean S.E. from at least three
independent experiments each withmultiple replicates (N 3,
n 4). KATP-dependent flux rate data is shown as mean S.D.
Statistical significancewas determined usingMann-WhitneyU
tests with a p value0.05 deemed statistically significant.
Inside-out excised patch-clamp recordings
Pipettes were made from soda lime glass microhematocrit
tubes (Kimble) and had a resistance of 1–2 megohms when
filled with pipette solution. The bath and pipette solutions
(KINT) contained (in mM): 140 KCl, 10 HEPES, 1 EGTA (pH 7.4
with KOH). Currents were recorded at a constant holding
potential of50mV in the absence and presence of nucleotides
as indicated. Where included, free Mg2 concentrations were
maintained at 0.5 mM by supplementation of MgCl2 as calcu-
lated using CaBuf (Katholieke Universiteit Leuven). Where
stated, porcine brain PIP2 (Avanti Polar Lipids) was applied
at 5 g/ml. Rapid solution exchange was attained using a
Dynaflow Resolve perfusion chip (Cellectricon). Experi-
ments were performed at 20–22 °C. KATP channel currents
in solutions of varying nucleotide concentrations were nor-
malized to the basal current in the absence of nucleotides,
and dose-response data were fit with a four-parameter Hill
fit according to Equation 3, using the Data Solver Function in
Microsoft Excel,






where the current in KINT  Imax  1; Imin is the normalized
minimum current observed in ATP/MgATP/glibenclamide;
[X] refers to the concentration of ATP/MgATP/glibenclamide;
IC50 is the concentration of half-maximal inhibition; and H
denotes the Hill coefficient.
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Data were tested for statistical significance using the Mann
WhitneyU test, and presented asmean S.E. in dose-response
plots, and as mean  S.D. in scatter plots showing IC50 values
from individual experiments.
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